Quick Answer
Lipocine Inc. reported Diluted EPS of $1.69 per share (loss) for fiscal year 2025.
Lipocine Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.69 | +46.2% |
| 2023 | -$3.14 | -46.0% |
| 2022 | -$2.15 | -21400.0% |
| 2021 | -$0.01 | +97.4% |
| 2020 | -$0.38 | +24.0% |
| 2019 | -$0.50 | +9.1% |
| 2018 | -$0.55 | +47.6% |
| 2017 | -$1.05 | -1.0% |
| 2016 | -$1.04 | +6.3% |
| 2015 | -$1.11 | +30.6% |
| 2014 | -$1.60 | -11.1% |
| 2013 | -$1.44 | -269.4% |
| 2012 | $0.85 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.59 | -34.1% | -43.9% |
| June 30, 2025 | -$0.41 | +26.8% | -17.1% |
| March 31, 2025 | -$0.35 | -153.0% | +20.5% |
| September 30, 2024 | -$0.44 | +65.4% | +21.4% |
| June 30, 2024 | -$0.56 | +17.6% | -184.8% |
| March 31, 2024 | $0.66 | +186.8% | +152.0% |
| September 30, 2023 | -$1.27 | -144.2% | -86.8% |
| June 30, 2023 | -$0.68 | -11.5% | +10.5% |
- Lipocine Inc. showed an increase of +46.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2012–2025 period, Lipocine Inc.’s diluted eps has declined by 298.8% (from $0.85 per share to $1.69 per share (loss)).
- The most recent figure is from Lipocine Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: